Bavarian Nordic hunts for best covid-19 vaccine production setup – may drop current manufacturer

If Bavarian Nordic successfully takes its covid-19 vaccine to the market, it will need to produce a lot of doses. The company cannot currently complete this task, and is looking for ways to secure its production – without guaranteeing a renewed contract with its current partner AGC Biologics.

Photo: Bavarian Nordic / PR

Bavarian Nordic cannot exclusively handle production of the company's covid-19 vaccine if and when it is ready for phase III and the subsequent commercialization.

In spite of expansions made in the firm's production apparatus in recent years, the firm lacks the equipment and capacity necessary for fulfilling production in this scale, which Bavarian Nordic Chief Financial Officer Henrik Juuel tells MedWatch in an interview.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs